John Logue

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations

Medicine, Nuclear Medicine, Radiation Oncology +17

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

David P. Dearnaley, Isabel Syndikus, Helen Mossop et al. · The Lancet Oncology · 2016 · 1.3K citations · Full text

Medicine, Oncology, Radiation Oncology +17

Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy

Juanita Crook, Christopher J. O’Callaghan, Graeme Duncan et al. · New England Journal of Medicine · 2012 · 497 citations · Full text

Medicine, Oncology, Urology +13

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

Oliver Sartor, Robert L. Coleman, Sten Nilsson et al. · The Lancet Oncology · 2014 · 491 citations

Medicine, Oncology, Pharmacology +17

Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix.

J A Loncaster, Adrian L. Harris, S.E. Davidson et al. · PubMed · 2001 · 465 citations · Full text

Medicine, Cell Biology, Oncology +15